.png){kind=small}
.png){kind=small}
BackTable / Urology / Podcast / Episode #193
Bladder Cancer Innovations: ESMO 2024 Highlights
with Dr. Andrea Apolo, Dr. Bogdana Schmidt
Catch up on the latest breakthroughs in bladder cancer management. In this episode of the BackTable Urology Podcast, Dr. Bogdana Schmidt (University of Utah) speaks with Dr. Andrea Apolo, a medical oncologist at the National Cancer Institute, about recent advancements in bladder cancer treatment presented at the 2024 European Society of Medical Oncology (ESMO) Congress.
Be part of the conversation. Put your sponsored messaging on this episode. Learn how.
BackTable, LLC (Producer). (2024, October 8). Ep. 193 – Bladder Cancer Innovations: ESMO 2024 Highlights [Audio podcast]. Retrieved from https://www.backtable.com
Stay Up To Date
Follow:
Subscribe:
Sign Up:
Podcast Contributors
Synopsis
They review pivotal trials like the NIAGARA and AMBASSADOR studies, the TAR-200 drug delivery system, the use of bladder-sparing treatment, and the role of ctDNA as a biomarker. Further, they detail the effectiveness of systemic therapies such as gemcitabine and pembrolizumab, the implications of perioperative immunotherapy, and the future role of antibody-drug conjugates. The conversation highlights the trend towards less invasive approaches while improving survival rates from bladder cancer.
Timestamps
00:00 - Introduction
03:49 - NIAGARA Trial
09:10 - Challenges in Bladder Cancer Treatment
18:56 - AMBASSADOR Trial
25:30 - Adjuvant Immunotherapy
29:30 - Exploring Biomarkers and ctDNA
36:34 - Surgery and Less Invasive Therapies
46:31 - Future Directions in Bladder Cancer Treatment
Resources
The Materials available on BackTable are provided for informational and educational purposes only and are not a substitute for the independent professional judgment of a qualified healthcare professional in diagnosing or treating patients. Any opinions, statements, or views expressed are those of the individual contributors and do not necessarily reflect those of the publisher, platform, or any affiliated organization.
Up Next
Articles
Topics
